Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06479720 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 9, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 31, 2024 to Jun 30, 2026
    • Study completion date: Jun 30, 2025 to Dec 31, 2026
    v4
  2. Study Identification, Study Status, Oversight, Study Designv3
  3. Enrollment target: 200 to 300
    • Interventions: Combination pharmacotherapy (Drug), Mirabegron with vaginal estrogen cream (Drug), Solifenacin with vaginal estrogen cream (Drug) to Combined pharmacotherapy with Solifenacin and Mirabegron (Drug), Mirabegron with vaginal estrogen cream (Drug), Solifenacin with vaginal…
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
Trial Details
NCT Number NCT06479720
Lead Sponsor Mackay Memorial Hospital
Conditions
(from sponsor)		 Effect of Drug, Urinary Bladder, Overactive
Related terms Urinary Bladder, Overactive
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov